Health
Phase I/II trial findings support use of CoronaVac vaccine in older individuals – News-Medical.Net
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and…
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
CoronaVac is an inactivated SARS-CoV-2 vaccine developed by Chinese pharmaceutical company Sinovac Life Sciences based in Beijing, China.
Writing in The Lancet Infectious…
-
Noosa News9 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News10 hours agoMotorcyclist dies in crash with truck
-
General24 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
General15 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging